Top of this page
Skip navigation, go straight to the content
UCB is a global biopharmaceutical company focusing on creating value for people living with neurology and immunology conditions.
Celebrating 90 years of innovation #UCB90
Twitter Feed
-
Guests discovering experiential booths in our newly refurbished UCB building #UCB90 https://t.co/fhOkWbjqxf
— UCB News (@ucb_news) 13.12.2018 -
We are delighted to have @alexanderdecroo, Deputy Prime Minister Minister of Finance and International Development, speaking on the importance of innovation at #UCB90 event. https://t.co/aNYIIvGUzE
— UCB News (@ucb_news) 13.12.2018 -
“UCB never stood still, constantly adapting itself, daring to reinvent itself and thereby progressing to the next step!” Evelyn du Monceau, Chair of the Board UCB #UCB90 https://t.co/sK2D0MDdOD
— UCB News (@ucb_news) 13.12.2018
Highlights
At UCB, we take our responsibility to the planet very seriously.
UCB Ventures, a strategic corporate venture fund established in 2017 to further strengthen UCB’s ability to create value from novel insights and technologies that can transform the lives of patients suffering from severe diseases, has announced its first direct investment.
